<DOC>
	<DOCNO>NCT01116778</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety probiotic eN-Lac® capsule ( Lactobacillus paracasei GMNL-32 ) treatment child perennial allergic rhinitis ( PAR ) .</brief_summary>
	<brief_title>Efficacy Safety Probiotics eN-Lac® Capsules Children With Perennial Allergic Rhinitis</brief_title>
	<detailed_description>This study PhaseIII clinical trial . According result PhaseII study , find optimal dose maximum effectiveness relieve nasal symptom eN-Lac® ( Lactobacillus paracasei GMNL-32 ) child PAR .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<criteria>Inclusion Criteria Subjects age 516 year old Subjects history perennial allergic rhinitis least 1 year . Subjects anyone follow allergy test result ( test result within 12 month study acceptable ) SkinPrick test : Wheal diameter 3 mm large negative control ( salt water ) least 1/2 diameter positive control ( histamine ) Positive reaction determine CAP system Positive reaction define CAP score≥2 Positive reaction determine MAST system Positive reaction define MAST score≥1 Subject 's mean nasal total symptom score ( NTSS ) throughout screen period ( 4 10 day ) ≥ 5 ≤ 10 ; least 3 day record screening period Subjects ' parent legally acceptable representative sign informed consent form . Exclusion Criteria Subjects clinically significant laboratory abnormality result ( hematology , biochemistry urinalysis test ) determine investigator ( test perform 14 day prior visit 1 baseline period use evaluate criterion ) . Subjects acute significant chronic sinusitis , severe persistent asthma , congenital immunodeficiency , massive wound oral cavity , use rhinitis medication , neuropsychiatric disorder , immunocompromised , chronic use tricyclic antidepressant . Subjects need take prohibited medication study take medication within correspond time frame indicate prior screen visit : Parenteral oral corticosteroid 30 day Nasal corticosteroids 30 day Topical use flurandrenolide 30 day Topical use clobetasol propionate 30 day Topical use halobetasol propionate 30 day Astemizole 30 day Ketotifene 21 day Nedocromil Sodium cromoglycate 14 day Loratadine 10 day Cetirizine 7 day Antileukotrienes 7 day Other H1 antihistamine 3 day Nasal decongestant 3 day Any food supplement include probiotic 3 day Subjects undergoing desensitization therapy within 3 month prior screen period subject vasomotor rhinitis . Subjects participate investigational drug trial within 4 week enter study . Subjects pregnant , lactate plan become pregnant . Subjects serious disease consider investigator could interfere performance NTSS result . Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period . Subjects lack physical integrity gastrointestinal tract , malabsorption syndrome , inability take oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>perennial allergic rhinitis</keyword>
	<keyword>probiotic</keyword>
	<keyword>Lactobacillus paracasei GMNL-32 ( eN-Lac® )</keyword>
	<keyword>efficacy safety</keyword>
</DOC>